Andere Sprachen BioLineRx Ltd. Nasdaq

Aktien

A2PNW3

US09071M2052

BLRX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 14.05.2024			% 5 Tage	% 1. Jan.
0,6449 ^USD	+3,68 %		-5,52 %	-58,92 %

17.04.	BioLineRx Ltd. kündigt Posterpräsentation über die Effizienz von Apheresezentren und CXCR4-Antagonisten einschließlich APHEXDA® (Motixafortide) bei Patienten mit Multiplem Myelom auf der ASFA-Jahrestagung 2024 an	CI
01.04.	BioLineRx-Aktien fallen nach $6 Millionen Registered Direct Offering	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024	06.05.
BioLineRx : Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	17.04.
BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	17.04.
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	10.04.
BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	10.04.
BioLineRx Announces $6 Million Registered Direct Offering	02.04.
BioLineRx Shares Fall After $6 Million Registered Direct Offering	01.04.
BioLineRx : Form 20-F/A (Amendment No. 1	28.03.
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	27.03.
BioLineRx : Annual Report on Form 20-F FOR 2023	26.03.
BioLineRx : Report of Periodic or Interim Report	26.03.
BioLineRx : Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	26.03.
BioLineRx Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024	20.03.
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production	04.03.
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production	04.03.
Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer	28.02.
BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®?	16.02.
BioLineRx : FORM F-3-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933	31.12.
BioLineRx : FORM S-8-registration of Ordinary Shares to be issued under the Plan	31.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen BioLineRx Ltd. Nasdaq

Aktien

A2PNW3

US09071M2052

BLRX

Andere Sprachen

Filter